期刊文献+

Application of EGFR targeted therapy in cancer

下载PDF
导出
摘要 EGFR signal pathway involved in many of cellular physiological and pathological processes including proliferation,apoptosis,angiogenesis,tumorigenesis and other complex processes.EGFR overexpression is associated with poorer prognosis and outcomes in many cancers.EGFR targeted therapy has been widely studied.In this review,we reviewed the mechanism,treatment in cancer and drug resistance for EGFR targeted therapy.
作者 Dan Liu
机构地区 [
出处 《Precision Medicine Research》 2019年第1期2-8,共7页 精准医学研究
  • 相关文献

参考文献5

二级参考文献38

  • 1Hunter T. Tyrosine phosphorylation: thirty years and counting. Curr Opin Cell Biol 2009; 21:140-6.
  • 2Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
  • 3Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009; 136: 823-37.
  • 4Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359: 1367-80.
  • 5Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16: 15-31.
  • 6Bose Rl, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, et al. Activating HER2 mutations in HER2 gene amplification negativebreast cancer. Cancer Discov 2013; 3: 224-37.
  • 7Lee J, Ou SH. Towards the goal of personalized medicine in gastric cancer-time to move beyond HER2 inhibition. Part I: Targeting receptor tyrosine kinase gene amplification. Discov Med 2013; 15: 333-41.
  • 8Stephens PI. Hunter C, Bignell G, Edkins S, Davies H, Teague J, et al.Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 2004; 431: 525-6.
  • 9Shawver LK, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002; 1: 117-23.
  • 10Hubbard SR. Protein tyrosine kinases: autoregulation and small-molecule inhibition. Curr Opin Struct Biol 2002; 12: 735-41.

共引文献108

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部